CYCLOPHOSPHAMIDE, METHOTREXATE, AND 5-FLUOROURACIL IN THE TREATMENT OF METASTATIC PROSTATE-CANCER - A SOUTHWEST-ONCOLOGY-GROUP STUDY

Background. Hormone-refractory metastatic prostate cancer remains a th erapeutic challenge. Cyclophosphamide, methotrexate, and 5-fluorouraci l (CMF), a drug combination that is active in solid tumors, was evalua ted using specific response criteria. Methods. Fifty-two eligible pati ents with measurable (19), evaluable (29), or bone scan only (4) metas tatic prostate cancer were treated with cyclophosphamide, 100 mg/m2 ev ery day by mouth, methotrexate, 15 Mg/M2 intravenously weekly, and 5-f luorouracil, 300 mg/m2 intravenously weekly. Treatment was given conti nuously unless interrupted by toxicity or disease progression. Results . There were two partial responses (7%) among the evaluable patients. Six (32%) measurable patients and four (14%) evaluable patients had st able disease. Median time to progression was 3.2 months for measurable and 2.8 months for evaluable disease patients. Median survivals were 10.9 and 10.2 months, respectively. There was no difference between th e two groups with regard to response rate or survival. Toxicity was ac ceptable and consisted primarily of myelosuppression. Conclusions. CMF is minimally active in hormone-refractory metastatic prostate cancer.